Abstract Bipolar disorder among pregnant women has deleterious effects on birth and child outcomes and is currently under-detected, not addressed effectively, or exacerbated through inappropriate treatment. The goal of this study was to identify perspectives of pregnant and postpartum women with bipolar disorder on barriers and facilitators to psychiatric treatment during pregnancy. In-depth interviews were conducted with pregnant and postpartum women who scored ≥ 10 on the Edinburgh Postnatal Depression Scale and met DSM-IV criteria for bipolar disorder I, II or not otherwise specified using the Mini International Neuropsychiatric Interview version 5.0. Interviews were transcribed, and resulting data were analyzed using a grounded theory approach to identify barriers and facilitators to bipolar disorder treatment access in pregnancy. Participant identified barriers included perception that psychiatric providers lack training and experience in the treatment of psychiatric illness during pregnancy, are reluctant to treat bipolar disorder among pregnant women, and believe that pharmacotherapy is not needed for psychiatric illness during pregnancy. Facilitators included participants' perception that providers' acknowledge risks associated with untreated or undertreated psychiatric illness during pregnancy and provide psycho-education about the risks, benefits and alternatives to pharmacotherapy. Psychiatric providers are critically important to the treatment of bipolar disorder and need knowledge and skills necessary to provide care during the perinatal period. Advancing psychiatric providers' knowledge/skills may improve access to pharmacotherapy for pregnant women with bipolar disorder.
Introduction
Bipolar disorder among perinatal women has deleterious effects on birth and child outcomes, and is associated with self-injury, substance use, suicide, and infanticide [1] . Despite availability of effective evidence-based treatments, many women with bipolar disorder are not identified and do not receive adequate treatment during pregnancy [2] . Even when bipolar disorder is recognized, women may experience treatment access barriers including psychiatric providers who are not adequately trained or who are uncomfortable initiating, continuing or maintaining psychopharmacology treatment for pregnant women [3] . Treatment access and adequacy is a critical issue because discontinuation of pharmacotherapy increases risk for illness relapse [1] .
There is a paucity of information on perceptions of women with bipolar disorder and their ability to access pharmacotherapy during pregnancy. The goals of this preliminary descriptive study were to identify: (1) barriers women with bipolar disorder face in accessing pharmacotherapy during pregnancy; and, (2) strategies to overcome barriers. In the discussion, we review how the findings inform intervention development aimed to improve pharmacotherapy access for women with bipolar disorder during pregnancy.
Methods
Participants were recruited from a purposeful sample of women from 12 weeks gestation to 24 months postpartum (n = 25) who scored ≥10 on the Edinburgh Postnatal Depression Scale [4] and met DSM-IV criteria [5] for bipolar disorder I, II or not otherwise specified using the Mini International Neuropsychiatric Interview version 5.0 [6] . Participants were recruited from four obstetric practices affiliated with a tertiary care referral center in Central Massachusetts. Informed consent was obtained and participants received a $15 gift card to compensate them for participation. This study was approved by the University of Massachusetts Medical School Institutional Review Board.
In-depth interviews lasting 20 min were conducted in which participants responded to study probes regarding the barriers and facilitators pregnant women with bipolar disorder face in accessing pharmacotherapy. All interviews were audiotaped. Recordings were cleaned of any identifying data, transcribed, and checked for accuracy.
Transcripts were uploaded into Dedoose [7] , a web-based software program that facilitates mixed methods data management for further coding, elaboration and specification of concepts and relationships. Interview content was organized theoretically, using a modified grounded theory approach with a phenomenological emphasis [8] . Using methods described by Miles & Huberman [9] , categorizing began with an initial set of preliminary codes for themes suggested from the literature, research aims and previous work. Codes were added as they emerged from the data until saturation was achieved, and initial transcript sections were re-categorized using the reformulated codes. Dedoose allows for the assembling of coded segments into selected configurations that facilitates identification of recurring patterns/clusters. Reliability was enhanced by the coding of data by more than one researcher.
Results
Participants represented a diverse and representative sample of women (Table 1) . Fourteen participants met DSM-IV criteria for bipolar disorder type I, five for bipolar disorder type II and six for bipolar disorder, not otherwise specified. As described below, similar themes reflecting barriers and facilitators mental health treatment during pregnancy were identified by participants.
Barriers
Refusal of Psychiatric Providers to Provide Pharmacotherapy to Perinatal Women Participants reported that general psychiatric providers are unwilling to provide pharmacotherapy, leaving them with limited treatment options. Participants noted that general psychiatric providers often discontinued psychotropic medications, without consideration of their impact on patients' mental health. Participants reported that such practices were common and made it difficult for them to stay psychiatrically healthy during pregnancy.
Lack of Training among General Psychiatric Providers
Participants expressed frustration that general psychiatric providers lacked sufficient knowledge about and training in management of pregnant women and thus are unable to provide appropriate and needed care.
"She doesn't know what she's doing.... after I explained to her everything that was going on with me... from top to bottom down the list... she told me that I was fine [and did not need medication treatment]... they need to find a doctor to fill her position because she's not appropriate, I need to see a doctor that is experienced with dealing with mental health issues with a pregnant person."
Limited Availability of Psychiatric Providers who will Treat Pregnant Women Participants reported long delays in getting treatment, noting that it takes four or five months to get an appointment with a psychiatric provider who accepts pregnant patients. One participant noted, "[Timely and accessible mental health care] wasn't available. It took a while to get help."
Facilitators
Working with a Psychiatrist who Specializes in Perinatal Psychiatry Getting referred to a provider who specializes in perinatal mental health was noted to facilitate appropriate treatment. Several participants perceived that their mental health would have benefitted if they had they been able to access such specialty care. "It's just if I could find the right person that would be safe seeing a pregnant woman... I could get the right treatment."
Psychiatric Providers' Understanding that Women Need to be Well to Care for their Babies Participants reported that when a psychiatric provider understood that they needed medications to function and feel well it empowered them and helped them to better care for their baby.
"I don't like being what I'm on, but I think the outcome of being happy and not depressed and being able to take care of my 3-year-old overpowers the downfall, the slight chance of risk of something being wrong with the baby."
Education Regarding the Risks and Benefits of Medication use during Pregnancy
Participants noted that knowledge about potential effects of both the illness and medication on the baby helped them feel that they were getting the best possible treatment and making the right choices about their care. Several participants noted that they appreciated hearing about studies and statistics as it built confidence in their treating provider. One participant noted, "I need to know what medications are safe in pregnancy... just to be able to function every day.".
Discussion
Psychiatric providers' reluctance to provide pharmacotherapy for pregnant women with bipolar disorder impedes women's ability to access evidence-based treatment and thus maintain or achieve psychiatric stability. Discontinuation of psychotropic medications by psychiatric providers, without consideration of their impact on patients' mental health, poses additional risk for women during a time of increased psychiatric vulnerability, which in turn may complicate birth, infant, and child outcomes [1] . Our findings build on prior studies in which obstetric providers reported that community mental health providers were reluctant to continue or initiate pharmacotherapy for pregnant women [3] . They also suggest that a better understanding of the benefits of and the need for treatment, regardless of pregnancy status, among psychiatric providers would enhance provision of evidence-based care for women.
Limitations include a small sample drawn from a single geographic region. Although our sampling focused on women with bipolar disorder, many of the barriers and facilitators may also apply to other psychiatric illnesses occurring during pregnancy. Including data on the perspectives of psychiatric providers would have enhanced our findings to understand provider perspectives on what makes bipolar disorder particularly challenging to manage during pregnancy. For example, is bipolar disorder more challenging to manage during pregnancy because providers perceive increased concerns about teratogenicity of mood stabilizers or antipsychotics as compared to antidepressants? Regardless, our study builds on previous research on barriers to perinatal depression treatment [3, 10] by including women with bipolar disorder. Eliciting the perspectives of women with bipolar disorder is essential because bipolar disorder occurs in 23% of perinatal women who screen positive for depression [11] and the barriers experienced by women with bipolar disorder may be different than for those with unipolar depression. Bipolar disorder requires different treatment than unipolar depression and is particularly complex and challenging during the perinatal period. Providers may be even more uncomfortable treating bipolar disorder because the illness and pharmacotherapy is more complicated, thus creating a double vulnerability (i.e., pregnancy and bipolar disorder) for women [3] .
The barriers identified by participants suggest important directions for interventions aimed to improve access to pharmacotherapy for bipolar disorder and possibly other psychiatric illness during pregnancy. While participants noted that access to a specialist in perinatal psychiatry facilitated care, many states, regions, and countries do not have such specialists-let alone a perinatal psychiatrist with expertise in bipolar disorders [12] . Thus, interventions need to focus on building the capacity of general psychiatrists to treat pregnant and postpartum women with affective disorders more broadly (i.e., not just perinatal depression). Advanced training in the management of both bipolar disorder and perinatal pharmacotherapy will be required to meet the needs of this population. Increased knowledge of the risk of psychiatric illness itself may mitigate abrupt discontinuation of psychotropic medications without adequate consideration of patients' mental health. Training for psychiatric providers should focus on how to weigh the risk of untreated illness and that of the medication.
Core competencies in perinatal mental health need to be developed and included in general psychiatrist residency training and maintenance of certification so the next generation of general psychiatrists can appropriately assess, counsel, and treat pregnant women in need of psychiatric treatment [12] . To build capacity for general psychiatric providers to provide bipolar disorder pharmacotherapy for pregnant and postpartum, improvement efforts could focus on developing an approach to care that includes expanded perinatal psychiatry training in residency and increased availability of consultation for general psychiatrists [13] . Research Involving Human Participants All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent Informed consent was obtained from all individual participants included in the study.
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